Please assign a menu to the primary menu location under menu

Enterprise

Enterprise Bank & Trust Co Sells 482 Shares of Johnson & Johnson (NYSE:JNJ)



Enterprise Bank & Trust Co trimmed its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 3.7% during the 1st quarter, HoldingsChannel reports. The fund owned 12,699 shares of the company’s stock after selling 482 shares during the quarter. Enterprise Bank & Trust Co’s holdings in Johnson & Johnson were worth $2,251,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Family CFO Inc acquired a new stake in Johnson & Johnson during the fourth quarter valued at approximately $26,000. Steward Financial Group LLC acquired a new stake in Johnson & Johnson during the fourth quarter valued at approximately $34,000. Jackson Wealth Management LLC boosted its holdings in Johnson & Johnson by 1.7% during the third quarter. Jackson Wealth Management LLC now owns 16,959 shares of the company’s stock valued at $40,000 after purchasing an additional 277 shares in the last quarter. Advocacy Wealth Management Services LLC boosted its holdings in Johnson & Johnson by 41.4% during the first quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock valued at $41,000 after purchasing an additional 67 shares in the last quarter. Finally, Iron Horse Wealth Management LLC boosted its holdings in Johnson & Johnson by 29.9% during the fourth quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company’s stock valued at $45,000 after purchasing an additional 61 shares in the last quarter. Hedge funds and other institutional investors own 68.78% of the company’s stock.

NYSE:JNJ opened at $182.29 on Friday. The stock’s fifty day moving average price is $177.70 and its two-hundred day moving average price is $173.40. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.14 and a current ratio of 1.39. The company has a market cap of $479.68 billion, a price-to-earnings ratio of 24.57, a P/E/G ratio of 3.55 and a beta of 0.66.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings data on Tuesday, April 19th. The company reported $2.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.60 by $0.07. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The firm had revenue of $23.43 billion for the quarter, compared to the consensus estimate of $23.62 billion. During the same quarter in the prior year, the business earned $2.59 EPS. The business’s revenue for the quarter was up 5.0% compared to the same quarter last year. On average, equities analysts predict that Johnson & Johnson will post 10.23 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 7th. Shareholders of record on Tuesday, May 24th were issued a dividend of $1.13 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.06. The ex-dividend date was Monday, May 23rd. This represents a $4.52 annualized dividend and a yield of 2.48%. Johnson & Johnson’s dividend payout ratio is currently 60.92%.

In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of the company’s stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the sale, the chief accounting officer now owns 15,473 shares in the company, valued at approximately $2,785,140. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider William Hait sold 29,699 shares of the company’s stock in a transaction on Thursday, April 21st. The shares were sold at an average price of $183.58, for a total transaction of $5,452,142.42. Following the sale, the insider now owns 80,236 shares of the company’s stock, valued at approximately $14,729,724.88. The disclosure for this sale can be found here. Insiders have sold a total of 78,161 shares of company stock valued at $13,895,302 in the last quarter. Corporate insiders own 0.35% of the company’s stock.

JNJ has been the topic of a number of recent research reports. Bank of America assumed coverage on Johnson & Johnson in a report on Wednesday, March 2nd. They set a “neutral” rating on the stock. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 17th. Citigroup reduced their target price on Johnson & Johnson from $210.00 to $205.00 in a report on Tuesday, May 17th. Raymond James boosted their target price on Johnson & Johnson from $195.00 to $196.00 and gave the stock an “outperform” rating in a report on Wednesday, April 20th. Finally, Credit Suisse Group boosted their target price on Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a report on Wednesday, April 20th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $190.50.

Johnson & Johnson Company Profile (Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)



Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.



READ SOURCE

Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.